Skip to main content
Top
Published in: International Journal of Hematology 5/2021

01-05-2021 | Filgrastim | Original Article

Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care

Authors: Olle Ringdén, Mats Remberger, Johan Törlén, Sigrun Finnbogadottir, Britt-Marie Svahn, Behnam Sadeghi

Published in: International Journal of Hematology | Issue 5/2021

Login to get access

Abstract

Following allogeneic hematopoietic cell transplantation (HCT), patients living near the hospital were treated at home instead of in isolation in the hospital. We analyzed cytokines using Luminex assays for the first 3 weeks after HCT and compared patients treated at home (n = 42) with matched patients isolated in the hospital (n = 37). In the multivariate analysis, patients treated at home had decreased GM-CSF, IFN-γ (p < 0.01), IL-13, IL-5 (p < 0.05), and IL-2 (p < 0.07). Bloodstream infections, anti-thymocyte globulin, G-CSF treatment, immunosuppression, reduced-intensity conditioning (RIC), related vs. unrelated donors, and graft source affected various cytokine levels. When patients with RIC were analyzed separately, home care patients had reduced G-CSF (p = 0.04) and increased vascular endothelial growth factor (VEGF, p = 0.001) at 3 weeks compared with hospital care patients. Patients with low GM-CSF (p < 0.036) and low IFNγ (p = 0.07) had improved survival. Acute GVHD grades III–IV was seen in 7% and 16% of home care and hospital care patients, respectively. One-year transplantation-related mortality was 7% and 16% and survival at 5 years was 69% and 57% in the two groups, respectively. To conclude, patients treated in the hospital showed varying increased levels of GM-CSF, IFN-γ, IL-13, G-CSF, IL-5, and IL-2 and decreased VEGF, which may contribute to acute GVHD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Thomas ED, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49(4):511–33.PubMedCrossRef Thomas ED, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49(4):511–33.PubMedCrossRef
3.
go back to reference Hoogerbrugge PM, et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet. 1995;345(8962):1398–402.PubMedCrossRef Hoogerbrugge PM, et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet. 1995;345(8962):1398–402.PubMedCrossRef
4.
go back to reference Slavin S, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756–63.PubMedCrossRef Slavin S, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756–63.PubMedCrossRef
5.
go back to reference Giralt S, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89(12):4531–6.PubMedCrossRef Giralt S, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89(12):4531–6.PubMedCrossRef
6.
go back to reference Hegenbart U, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006;24(3):444–53.PubMedCrossRef Hegenbart U, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006;24(3):444–53.PubMedCrossRef
7.
go back to reference Ringden O, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients age > 69 years with acute myelogenous leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25(10):1975–83.PubMedCrossRef Ringden O, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients age > 69 years with acute myelogenous leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25(10):1975–83.PubMedCrossRef
8.
go back to reference Broxmeyer HE, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA. 1989;86(10):3828–32.PubMedPubMedCentralCrossRef Broxmeyer HE, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA. 1989;86(10):3828–32.PubMedPubMedCentralCrossRef
9.
go back to reference Luznik L, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–50.PubMedPubMedCentralCrossRef Luznik L, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–50.PubMedPubMedCentralCrossRef
10.
go back to reference Ringden O, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol. 2009;27(27):4570–7.PubMedCrossRef Ringden O, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol. 2009;27(27):4570–7.PubMedCrossRef
11.
go back to reference Yanada M, et al. Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission. Eur J Haematol. 2016;97(3):278–87.PubMedCrossRef Yanada M, et al. Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission. Eur J Haematol. 2016;97(3):278–87.PubMedCrossRef
12.
go back to reference Hoshino T, et al. Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen. Int J Hematol. 2019;109(4):463–9.PubMedCrossRef Hoshino T, et al. Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen. Int J Hematol. 2019;109(4):463–9.PubMedCrossRef
13.
go back to reference Morishima Y, et al. Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(8):1197–203.PubMedPubMedCentralCrossRef Morishima Y, et al. Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(8):1197–203.PubMedPubMedCentralCrossRef
14.
go back to reference Buckner CD, et al. Protective environment for marrow transplant recipients: a prospective study. Ann Intern Med. 1978;89(6):893–901.PubMedCrossRef Buckner CD, et al. Protective environment for marrow transplant recipients: a prospective study. Ann Intern Med. 1978;89(6):893–901.PubMedCrossRef
15.
go back to reference Skinhoj P, et al. Strict protective isolation in allogenic bone marrow transplantation: effect on infectious complications, fever and graft versus host disease. Scand J Infect Dis. 1987;19(1):91–6.PubMedCrossRef Skinhoj P, et al. Strict protective isolation in allogenic bone marrow transplantation: effect on infectious complications, fever and graft versus host disease. Scand J Infect Dis. 1987;19(1):91–6.PubMedCrossRef
16.
go back to reference Svahn BM, et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood. 2002;100(13):4317–24.PubMedCrossRef Svahn BM, et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood. 2002;100(13):4317–24.PubMedCrossRef
17.
go back to reference Ringden O, et al. Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Int J Hematol. 2018;107(4):478–85.PubMedCrossRef Ringden O, et al. Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Int J Hematol. 2018;107(4):478–85.PubMedCrossRef
18.
go back to reference Svahn BM, Ringden O, Remberger M. Treatment costs and survival in patients with grades III–IV acute graft-versus-host disease after allogenic hematopoietic stem cell transplantation during three decades. Transplantation. 2006;81(11):1600–3.PubMedCrossRef Svahn BM, Ringden O, Remberger M. Treatment costs and survival in patients with grades III–IV acute graft-versus-host disease after allogenic hematopoietic stem cell transplantation during three decades. Transplantation. 2006;81(11):1600–3.PubMedCrossRef
19.
go back to reference Svahn BM, Ringden O, Remberger M. Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36(6):511–6.PubMedCrossRef Svahn BM, Ringden O, Remberger M. Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36(6):511–6.PubMedCrossRef
20.
go back to reference Ringden O, et al. Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(2):314–20.PubMedCrossRef Ringden O, et al. Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(2):314–20.PubMedCrossRef
21.
go back to reference van Bekkum DW, Knaan S. Role of bacterial microflora in development of intestinal lesions from graft-versus-host reaction. J Natl Cancer Inst. 1977;58(3):787–90.PubMedCrossRef van Bekkum DW, Knaan S. Role of bacterial microflora in development of intestinal lesions from graft-versus-host reaction. J Natl Cancer Inst. 1977;58(3):787–90.PubMedCrossRef
22.
go back to reference Boström L, et al. A role of herpes virus serology for the development of acute graft-versus-host disease. Leukaemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant. 1990;5(5):321–6.PubMed Boström L, et al. A role of herpes virus serology for the development of acute graft-versus-host disease. Leukaemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant. 1990;5(5):321–6.PubMed
23.
go back to reference van der Velden WJ, et al. The incidence of acute graft-versus-host disease increases with Candida colonization depending the dectin-1 gene status. Clin Immunol. 2010;136(2):302–6.PubMedCrossRef van der Velden WJ, et al. The incidence of acute graft-versus-host disease increases with Candida colonization depending the dectin-1 gene status. Clin Immunol. 2010;136(2):302–6.PubMedCrossRef
24.
go back to reference Blennow O, Mattsson J, Remberger M. Pre-engraftment blood stream infection is a risk factor for acute GVHD grades II–IV. Bone Marrow Transplant. 2013;48(12):1583–4.PubMedCrossRef Blennow O, Mattsson J, Remberger M. Pre-engraftment blood stream infection is a risk factor for acute GVHD grades II–IV. Bone Marrow Transplant. 2013;48(12):1583–4.PubMedCrossRef
25.
go back to reference Sorror ML, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9.PubMedPubMedCentralCrossRef Sorror ML, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9.PubMedPubMedCentralCrossRef
26.
go back to reference Törlén J, et al. Impact of pretransplantation indices in hematopoietic stem cell transplantation: knowledge of center-specific outcome data is pivotal before making index-based decisions. Biol Blood Marrow Transplant. 2017;23(4):677–83.PubMedCrossRef Törlén J, et al. Impact of pretransplantation indices in hematopoietic stem cell transplantation: knowledge of center-specific outcome data is pivotal before making index-based decisions. Biol Blood Marrow Transplant. 2017;23(4):677–83.PubMedCrossRef
27.
go back to reference Ringden O, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood. 1994;83(9):2723–30.PubMedCrossRef Ringden O, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood. 1994;83(9):2723–30.PubMedCrossRef
28.
go back to reference Ringdén OET, Aschan J, Garming-Legert K, Le Blanc K, Hägglund H, Omazic B, Svenberg P, Dahllöf G, Mattsson J, Ljungman P, Remberger M. A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. J Intern Med. 2013;274:153–62.PubMedCrossRef Ringdén OET, Aschan J, Garming-Legert K, Le Blanc K, Hägglund H, Omazic B, Svenberg P, Dahllöf G, Mattsson J, Ljungman P, Remberger M. A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. J Intern Med. 2013;274:153–62.PubMedCrossRef
29.
go back to reference Ringden O, et al. Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases. Bone Marrow Transplant. 2007;39(7):383–8.PubMedCrossRef Ringden O, et al. Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases. Bone Marrow Transplant. 2007;39(7):383–8.PubMedCrossRef
30.
go back to reference Ringden O, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant. 1995;15(4):619–25.PubMed Ringden O, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant. 1995;15(4):619–25.PubMed
31.
go back to reference Forslow U, et al. Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2012;89(3):220–7.PubMedCrossRef Forslow U, et al. Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2012;89(3):220–7.PubMedCrossRef
32.
go back to reference Schaffer M, et al. Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens. 2003;62(3):243–50.PubMedCrossRef Schaffer M, et al. Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens. 2003;62(3):243–50.PubMedCrossRef
33.
go back to reference Schmitz N, et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998;21(10):995–1003.PubMedCrossRef Schmitz N, et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998;21(10):995–1003.PubMedCrossRef
34.
go back to reference Ringden O, et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood. 1999;94(2):455–64.PubMedCrossRef Ringden O, et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood. 1999;94(2):455–64.PubMedCrossRef
35.
go back to reference Storb R, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood. 1989;73(6):1729–34.PubMedCrossRef Storb R, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood. 1989;73(6):1729–34.PubMedCrossRef
36.
go back to reference Ringden O, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood. 1993;81(4):1094–101.PubMedCrossRef Ringden O, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood. 1993;81(4):1094–101.PubMedCrossRef
37.
go back to reference Torlen J, et al. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. Haematologica. 2016;101(11):1417–25.PubMedPubMedCentralCrossRef Torlen J, et al. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. Haematologica. 2016;101(11):1417–25.PubMedPubMedCentralCrossRef
38.
go back to reference Storb R, Thomas ED. Graft-versus-host disease in dog and man: the Seattle experience. Immunol Rev. 1985;88:215–38.PubMedCrossRef Storb R, Thomas ED. Graft-versus-host disease in dog and man: the Seattle experience. Immunol Rev. 1985;88:215–38.PubMedCrossRef
39.
go back to reference Carlens S, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant. 1998;22(8):755–61.PubMedCrossRef Carlens S, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant. 1998;22(8):755–61.PubMedCrossRef
40.
go back to reference Filipovich AH, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–56.PubMedCrossRef Filipovich AH, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–56.PubMedCrossRef
41.
go back to reference Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–81.CrossRef Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–81.CrossRef
42.
43.
go back to reference Tugues S, et al. Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells. Sci Transl Med. 2018;10(469):1–12. Tugues S, et al. Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells. Sci Transl Med. 2018;10(469):1–12.
44.
go back to reference Mizuno S, et al. Gamma-interferon production capacity and T lymphocyte subpopulation after allogeneic bone marrow transplantation. Transplantation. 1986;41(3):311–5.PubMedCrossRef Mizuno S, et al. Gamma-interferon production capacity and T lymphocyte subpopulation after allogeneic bone marrow transplantation. Transplantation. 1986;41(3):311–5.PubMedCrossRef
46.
go back to reference Toubai T, et al. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD)—are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)? Curr Stem Cell Res Ther. 2012;7:229–39.PubMedCrossRef Toubai T, et al. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD)—are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)? Curr Stem Cell Res Ther. 2012;7:229–39.PubMedCrossRef
47.
go back to reference Chistiakov DA, et al. The impact of interferon-regulatory factors to macrophage differentiation and polarization into M1 and M2. Immunobiology. 2018;223(1):101–11.PubMedCrossRef Chistiakov DA, et al. The impact of interferon-regulatory factors to macrophage differentiation and polarization into M1 and M2. Immunobiology. 2018;223(1):101–11.PubMedCrossRef
48.
go back to reference Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Rev. 2003;17(4):187–94.PubMedCrossRef Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Rev. 2003;17(4):187–94.PubMedCrossRef
49.
go back to reference Jordan WJ, et al. IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation. Blood. 2004;103(2):717–24.PubMedCrossRef Jordan WJ, et al. IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation. Blood. 2004;103(2):717–24.PubMedCrossRef
50.
go back to reference Minty A, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature. 1993;362(6417):248–50.PubMedCrossRef Minty A, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature. 1993;362(6417):248–50.PubMedCrossRef
51.
go back to reference Ringdén O, et al. Markedly elevated serum IgE levels following allogeneic and syngeneic bone marrow transplantation. Blood. 1983;61(6):1190–5.PubMedCrossRef Ringdén O, et al. Markedly elevated serum IgE levels following allogeneic and syngeneic bone marrow transplantation. Blood. 1983;61(6):1190–5.PubMedCrossRef
52.
go back to reference Gutiérrez-García G, et al. A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe. Bone Marrow Transplant. 2020;55(5):965–73.PubMedCrossRef Gutiérrez-García G, et al. A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe. Bone Marrow Transplant. 2020;55(5):965–73.PubMedCrossRef
53.
go back to reference Remberger M, et al. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant. 1999;24(8):823–30.PubMedCrossRef Remberger M, et al. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant. 1999;24(8):823–30.PubMedCrossRef
54.
go back to reference Holler E, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75(4):1011–6.PubMedCrossRef Holler E, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75(4):1011–6.PubMedCrossRef
55.
go back to reference Ustun C, et al. Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2019;54(8):1254–65.PubMedCrossRef Ustun C, et al. Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2019;54(8):1254–65.PubMedCrossRef
56.
go back to reference Ringden O, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2004;22(3):416–23.PubMedCrossRef Ringden O, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2004;22(3):416–23.PubMedCrossRef
57.
go back to reference Ringden O, et al. Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease. Transplantation. 2010;90(9):1022–9.PubMedCrossRef Ringden O, et al. Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease. Transplantation. 2010;90(9):1022–9.PubMedCrossRef
58.
go back to reference Morris ES, et al. Induction of natural killer T cell-dependent alloreactivity by administration of granulocyte colony-stimulating factor after bone marrow transplantation. Nat Med. 2009;15(4):436–41.PubMedCrossRef Morris ES, et al. Induction of natural killer T cell-dependent alloreactivity by administration of granulocyte colony-stimulating factor after bone marrow transplantation. Nat Med. 2009;15(4):436–41.PubMedCrossRef
59.
go back to reference Olsson R, et al. GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants. Eur J Haematol. 2010;84(4):323–31.PubMedCrossRef Olsson R, et al. GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants. Eur J Haematol. 2010;84(4):323–31.PubMedCrossRef
60.
go back to reference Ringden O, et al. A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. J Intern Med. 2013;274(2):153–62.PubMedCrossRef Ringden O, et al. A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. J Intern Med. 2013;274(2):153–62.PubMedCrossRef
61.
go back to reference Poiret T, et al. Reduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease (GVHD) in children and adults. BMC Immunol. 2014;15:25.PubMedPubMedCentralCrossRef Poiret T, et al. Reduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease (GVHD) in children and adults. BMC Immunol. 2014;15:25.PubMedPubMedCentralCrossRef
62.
go back to reference Dean RM, et al. Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J Clin Oncol. 2008;26(35):5735–41.PubMedPubMedCentralCrossRef Dean RM, et al. Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J Clin Oncol. 2008;26(35):5735–41.PubMedPubMedCentralCrossRef
63.
go back to reference Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft- vs. -host disease. Biol Blood Marrow Transplant. 1999;5(6):347–56.PubMedCrossRef Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft- vs. -host disease. Biol Blood Marrow Transplant. 1999;5(6):347–56.PubMedCrossRef
64.
go back to reference Ringden O, et al. Decreased risk of acute graft-versus-host disease using reduced intensity conditioning compared to myeloablative conditioning is independent of donor-recipient t-cell chimerism. Bone Marrow Transplant. 2014;49:S536–S536. Ringden O, et al. Decreased risk of acute graft-versus-host disease using reduced intensity conditioning compared to myeloablative conditioning is independent of donor-recipient t-cell chimerism. Bone Marrow Transplant. 2014;49:S536–S536.
65.
go back to reference Min CK, et al. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38(2):149–56.PubMedCrossRef Min CK, et al. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38(2):149–56.PubMedCrossRef
66.
go back to reference Nachbaur D, et al. Vascular endothelial growth factor and activin-a serum levels following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(8):942–7.PubMedCrossRef Nachbaur D, et al. Vascular endothelial growth factor and activin-a serum levels following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(8):942–7.PubMedCrossRef
67.
go back to reference Remberger M, Ringdén O. Serum levels of cytokines after bone marrow transplantation: increased IL-8 levels during severe veno-occlusive disease of the liver. Eur J Haematol. 1997;59(4):254–62.PubMedCrossRef Remberger M, Ringdén O. Serum levels of cytokines after bone marrow transplantation: increased IL-8 levels during severe veno-occlusive disease of the liver. Eur J Haematol. 1997;59(4):254–62.PubMedCrossRef
68.
go back to reference Ringden O, et al. Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies. Transplantation. 1998;66(5):620–5.PubMedCrossRef Ringden O, et al. Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies. Transplantation. 1998;66(5):620–5.PubMedCrossRef
69.
go back to reference Finke J, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–64.PubMedCrossRef Finke J, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–64.PubMedCrossRef
70.
go back to reference Shono Y, et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med. 2016;8(339):339–71.CrossRef Shono Y, et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med. 2016;8(339):339–71.CrossRef
Metadata
Title
Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care
Authors
Olle Ringdén
Mats Remberger
Johan Törlén
Sigrun Finnbogadottir
Britt-Marie Svahn
Behnam Sadeghi
Publication date
01-05-2021
Publisher
Springer Singapore
Published in
International Journal of Hematology / Issue 5/2021
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-021-03087-w

Other articles of this Issue 5/2021

International Journal of Hematology 5/2021 Go to the issue

Progress in Hematology

Evolution of CML treatment

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine